BMPs and gene therapy for spinal fusion: Summary statement

Harvinder S. Sandhu, Scott D. Boden, Howard An, James Kang, James Neil Weinstein

    Research output: Contribution to journalShort surveypeer-review

    10 Scopus citations


    The use of biologic technologies to engender spinal fusion is at various stages of scientific and clinical development. Recombinant human bone morphogenetic protein 2 is now available for clinical use in anterior lumbar intervertebral fusion and has been extensively studied in other spinal fusion applications. Recombinant bone morphogenetic protein 7 is under examination in regulated clinical trials. Gene therapy technologies are in the preclinical stage of development. In time, biologic interventions will continue to capture greater roles in the treatment of spinal disease.

    Original languageEnglish (US)
    Pages (from-to)S85
    Issue number15 SUPPL.
    StatePublished - Aug 1 2003

    ASJC Scopus subject areas

    • Orthopedics and Sports Medicine
    • Clinical Neurology


    Dive into the research topics of 'BMPs and gene therapy for spinal fusion: Summary statement'. Together they form a unique fingerprint.

    Cite this